Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment

摘要: Introduction: Pemetrexed is active as first-line treatment of malignant pleural mesothelioma. The objective was to evaluate its activity second-line treatment. Methods: Patients had disease progression mesothelioma after previous platinum-based regimens without pemetrexed. Treatment pemetrexed alone or combined with carboplatin. dosing 500 mg/m 2 and carboplatin AUC (area under the curve) 5 once every 3 weeks. Results: Thirty-nine patients were included: 28 Danish received (three third-line treatment), whereas 11 Norwegian plus Most men (90%), epithelial subtype (85%), International Mesothelioma Interest Group stages III IV (77%). Median age 62 years (range, 30–77). median number courses six 1–23). Common Toxicity Criteria grade 4 toxicity occurred only respect leukocytopenia (pemetrexed: 14% patients; carboplatin: 9%) thrombocytopenia 7%; 18%). One patient receiving died sepsis. Partial response rates 21% 18%, time 21 weeks 4–92) 32 4–128+), survival 42 4–99) 39 10–128+) carboplatin, respectively. Conclusions: generally well tolerated noteworthy in may be considered for